{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:41:05Z","timestamp":1793814065754,"version":"4.6.1"},"reference-count":55,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.2217\/imt.15.112","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T20:41:18Z","timestamp":1453495278000},"page":"107-115","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Golimumab for Treatment of Axial Spondyloarthritis"],"prefix":"10.1080","volume":"8","author":[{"given":"Valeria","family":"Rios Rodriguez","sequence":"first","affiliation":[{"name":"Rheumatology, Medical Department I, Campus Benjamin Franklin, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 10117Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Rheumatology, Medical Department I, Campus Benjamin Franklin, Charit\u00e9 Universit\u00e4tsmedizin Berlin, 10117Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,1,22]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21688"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24483"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39225"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041137"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052878"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019174"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054098"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151563"},{"key":"e_1_3_3_13_1","unstructured":"Golimumab approval by EMA on 2015. www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000992\/WC500187055.pdf."},{"issue":"11","key":"e_1_3_3_14_1","first-page":"S232","article-title":"Secukinumab, a monoclonal antibody to Interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a Phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing","volume":"66","author":"Sieper J","year":"2014","unstructured":"Sieper J , BraunJ, BaraliakosXet al. Secukinumab, a monoclonal antibody to Interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a Phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Arthritis Rheum.66(Suppl. 11), S232 (2014).","journal-title":"Arthritis Rheum."},{"key":"e_1_3_3_15_1","volume-title":"2014 ACR\/ARHP Annual Meeting 2014","author":"Baeten D","year":"2014","unstructured":"Baeten D , BraunJ, BaraliakosXet al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week Phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Presented at: 2014 ACR\/ARHP Annual Meeting 2014. Boston, MA, USA, 14\u201319November2014 (Abstract 538)."},{"key":"e_1_3_3_16_1","unstructured":"Amgen to terminate participation in co-development and commercialization of brodalumab. www.amgen.com\/media\/media_pr_detail.jsp?releaseID=2052862."},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204248"},{"issue":"6","key":"e_1_3_3_18_1","first-page":"322","article-title":"Pharmaceutical approval update","volume":"34","author":"Goldenberg MM.","year":"2009","unstructured":"Goldenberg MM. Pharmaceutical approval update. PT34(6), 322\u2013327 (2009).","journal-title":"PT"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.5.9286"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3229"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.12304"},{"issue":"7","key":"e_1_3_3_22_1","first-page":"1430","article-title":"Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation","volume":"29","author":"Grisar J","year":"2002","unstructured":"Grisar J , BerneckerPM, AringerMet al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J. Rheumatol.29(7), 1430\u20131436 (2002).","journal-title":"J. Rheumatol."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201697"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202089"},{"key":"e_1_3_3_25_1","unstructured":"Golimumab (Simponi) label approved by FDA on April 2009. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125289s070lbl.pdf."},{"key":"e_1_3_3_26_1","unstructured":"Product information: Golimumab (Simponi) last updated 22 June 2015. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000992\/WC500052368.pdf."},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006298188"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.11.015"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009340782"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205862"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200859"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34442"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23901"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23471"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2794"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203075"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200308"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39257"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27660"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24941"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085852"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2904"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.10.011"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204195"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.7430"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0134-5"},{"issue":"30","key":"e_1_3_3_52_1","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2013California, 2002\u20132003","volume":"53","author":"Centers for disease control and prevention","year":"2004","unstructured":"Centers for disease control and prevention . Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2013California, 2002\u20132003. MMWR Morb. Mortal. Wkly Rep.53(30), 683\u2013686 (2004).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"e_1_3_3_53_1","unstructured":"Golimumab approval by FDA for ulcerative colitis 16 May 2013. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm352383.htm."},{"issue":"4","key":"e_1_3_3_54_1","first-page":"S118","article-title":"Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis","volume":"27","author":"Franke LC","year":"2009","unstructured":"Franke LC , AmentAJ, Van De LaarMA, BoonenA, SeverensJL. Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis. Clin. Exp. Rheumatol.27(4 Suppl. 55), S118\u2013S123 (2009).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182514093"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090242"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.121327"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.15.112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:34:55Z","timestamp":1715996095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.15.112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,22]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.2217\/imt.15.112"],"URL":"https:\/\/doi.org\/10.2217\/imt.15.112","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-09-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}